BioSpace News Archive

Medovate announced that the game-changing regional anesthesia technology SAFIRA® has been added to the Vizient Group Purchasing Organization contract alongside the Konica Minolta SONIMAGE® HS2 Ultrasound System.

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed cGMP manufacturing of a multi-kilogram lot of cepharanthine-2HCl for use in the final drug product production of PD-001, its patented, orally bioavailable version of cepharanthine.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the “Clinical Trial Financing Alternatives”)

Saluda Medical Pty Limited, a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, announced the appointment of Laureen DeBuono to its board of directors.

BRAINBox Solutions, Inc announced that the U.S. Patent & Trademark Office issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury, also known as concussion, using Brain Derived Neurotrophic Factor.

Araris Biotech AG today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

The latest market analysis report published by Reports and Data, titled ‘Global Dystrophic Epidermolysis Bullosa Treatment Market – Forecast to 2030,’ thoroughly examines the Dystrophic Epidermolysis Bullosa Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Small Lymphocytic Lymphoma Treatment Market – Forecast to 2030,’ thoroughly examines the Small Lymphocytic Lymphoma Treatment industry to provide essential data & information for the targeted readers.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on October 3, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards (RSUs).

Quantgene, a Santa Monica, California, and Berlin, Germany-based biotechnology, cloud and artificial intelligence company, will host a delegation of healthcare executives and scientific leaders from Baden-Württemberg at its headquarters on October 5.